Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camille Tlemsani

Showing results (1-10 of 55) with videos related to

Pageof 6
Sort By:
Bulletin Du Cancer|August 21, 2025
[TRANSFORM-O: A new training program in translational research offered by the French Society of Cancer (SFC) and the French National College of Oncology Teachers (CNEC)]Stanislas Quesada, Camille Tlemsani, Christophe Massard, et al.
Expert Opinion on Investigational Drugs|September 25, 2023
<i>NF1</i> alterations in cancers: therapeutic implications in precision medicineJean-Stéphane Giraud, Ivan Bièche, Éric Pasmant, et al.
NPJ Precision Oncology|February 10, 2024
NF1 mutations as biomarker of response to immune checkpoint blockades for lung adenocarcinoma patientsJean-Stéphane Giraud, Anne Jouinot, Eric Pasmant, et al.
Targeted Oncology|November 18, 2011
Posterior reversible encephalopathy syndrome induced by anti-VEGF agentsCamille Tlemsani, Olivier Mir, Pascaline Boudou-Rouquette, et al.
BMC Palliative Care|March 14, 2020
First referral to an integrated onco-palliative care program: a retrospective analysis of its timingClaire Barth, Isabelle Colombet, Vincent Montheil, et al.
Clinical Nutrition ESPEN|October 2, 2022
Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patientsCamille Tlemsani, Jean-Philippe Durand, Bruno Raynard, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 25, 2016
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a reviewPascaline Boudou-Rouquette, Camille Tlemsani, Benoit Blanchet, et al.
Thyroid : Official Journal of the American Thyroid Association|December 21, 2019
Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION TrialOlivier Huillard, Anne Jouinot, Camille Tlemsani, et al.
Annals of Nutrition & Metabolism|December 23, 2019
Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung CancerGuillaume Ulmann, Anne Jouinot, Camille Tlemsani, et al.
European Journal of Radiology|August 9, 2024
Performance of AI for preoperative CT assessment of lung metastases: Retrospective analysis of 167 patientsGiorgio Maria Masci, Guillaume Chassagnon, Marco Alifano, et al.
Pageof 6

Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Bulletin Du Cancer|August 21, 2025
[TRANSFORM-O: A new training program in translational research offered by the French Society of Cancer (SFC) and the French National College of Oncology Teachers (CNEC)]Stanislas Quesada, Camille Tlemsani, Christophe Massard, et al.
Expert Opinion on Investigational Drugs|September 25, 2023
<i>NF1</i> alterations in cancers: therapeutic implications in precision medicineJean-Stéphane Giraud, Ivan Bièche, Éric Pasmant, et al.
NPJ Precision Oncology|February 10, 2024
NF1 mutations as biomarker of response to immune checkpoint blockades for lung adenocarcinoma patientsJean-Stéphane Giraud, Anne Jouinot, Eric Pasmant, et al.
Targeted Oncology|November 18, 2011
Posterior reversible encephalopathy syndrome induced by anti-VEGF agentsCamille Tlemsani, Olivier Mir, Pascaline Boudou-Rouquette, et al.
BMC Palliative Care|March 14, 2020
First referral to an integrated onco-palliative care program: a retrospective analysis of its timingClaire Barth, Isabelle Colombet, Vincent Montheil, et al.
Clinical Nutrition ESPEN|October 2, 2022
Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patientsCamille Tlemsani, Jean-Philippe Durand, Bruno Raynard, et al.
Expert Opinion on Drug Metabolism & Toxicology|August 25, 2016
Clinical pharmacology, drug-drug interactions and safety of pazopanib: a reviewPascaline Boudou-Rouquette, Camille Tlemsani, Benoit Blanchet, et al.
Thyroid : Official Journal of the American Thyroid Association|December 21, 2019
Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION TrialOlivier Huillard, Anne Jouinot, Camille Tlemsani, et al.
Annals of Nutrition & Metabolism|December 23, 2019
Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung CancerGuillaume Ulmann, Anne Jouinot, Camille Tlemsani, et al.
European Journal of Radiology|August 9, 2024
Performance of AI for preoperative CT assessment of lung metastases: Retrospective analysis of 167 patientsGiorgio Maria Masci, Guillaume Chassagnon, Marco Alifano, et al.
Pageof 6